Personal information

No personal information available

Activities

Collapse all

Employment (1)

University of Ljubljana: Ljubljana, SI

2010-04-01 to present | Fellow Researcher (Pharmaceutical Biology )
Employment
Source: Self-asserted source
Rade Injac

Education and qualifications (5)

Project Management Institute: Newtown Grant, Pennsylvania, US

2016-06-16 to present | Certified PM (Project Management )
Education
Source: Self-asserted source
Rade Injac

University of Ljubljana: Ljubljana, SI

2009-10-01 to 2022-12-09 | Mag. Spec. (Pharmaceutical Chamber )
Education
Source: Self-asserted source
Rade Injac

IEDC-Bled School of Management: Bled, SI

2016-02-01 to 2017-12-12 | Master (Business Administration )
Education
Source: Self-asserted source
Rade Injac

University of Ljubljana: Ljubljana, SI

2003-10-01 to 2008-12-05 | Ph.D. (Faculty of Pharmacy )
Education
Source: Self-asserted source
Rade Injac

University of Belgrade: Belgrade, RS

1997-10-01 to 2003-03-07 | Bachelor (Faculty of Pharmacy )
Education
Source: Self-asserted source
Rade Injac

Works (12)

Analysis of doxorubicin and fullerenol in rat serum by micellar electrokinetic capillary chromatography

Acta Pharmaceutica
2024-09-01 | Journal article
DOI: 10.2478/acph-2024-0026
Contributors: Rade Injac; Miranda Sertić; Nina Kočevar Glavač
Source: check_circle
Crossref

Preliminary investigation of organ-protective effects of fullerenol in vivo in acute toxicity during doxorubicin therapy in healthy pigs

RPS Pharmacy and Pharmacology Reports
2024-01-01 | Journal article
DOI: 10.1093/rpsppr/rqad038
Contributors: Rade Injac; Aleksandar Djordjevic; Borut Strukelj
Source: check_circle
Crossref

Spermatogenesis recovery treatment in less than four months from zero to almost 16 million sperms per milliliter after several cycles of steroids in 44‐year‐old healthy man

Clinical Case Reports
2023-11 | Journal article
DOI: 10.1002/ccr3.8159
Contributors: Rade Injac
Source: check_circle
Crossref

Spermatogenesis recovery treatment in less than four months from zero to almost 16 million sperms per milliliter after several cycles of steroids in 44-year-old healthy man

2023-09-12 | Preprint
DOI: 10.22541/au.169449510.07728336/v1
Contributors: Rade Injac
Source: check_circle
Crossref

Potential Medical Use of Fullerenols After Two Decades of Oncology Research

Technology in Cancer Research & Treatment
2023-01 | Journal article | Author
DOI: 10.1177/15330338231201515
Part of ISSN: 1533-0346
Part of ISSN: 1533-0338
Contributors: Rade Injac
Source: Self-asserted source
Rade Injac
grade
Preferred source (of 2)‎

Acute doxorubicin pulmotoxicity in rats with malignant neoplasm is effectively treated with fullerenol C60(OH)24 through inhibition of oxidative stress

Pharmacological Reports
2009-03 | Journal article
DOI: 10.1016/s1734-1140(09)70041-6
Part of ISSN: 1734-1140
Contributors: Rade Injac; Natasa Radic; Biljana Govedarica; Martina Perse; Anton Cerar; Aleksandar Djordjevic; Borut Strukelj
Source: Self-asserted source
Rade Injac

Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer

Biomaterials
2009-02 | Journal article
DOI: 10.1016/j.biomaterials.2008.10.060
Part of ISSN: 0142-9612
Contributors: Rade Injac; Martina Perse; Manica Cerne; Nejka Potocnik; Natasa Radic; Biljana Govedarica; Aleksandar Djordjevic; Anton Cerar; Borut Strukelj
Source: Self-asserted source
Rade Injac

Activity of Antioxidative Enzymes in Erythrocytes after a Single Dose Administration of Doxorubicin in Rats Pretreated with Fullerenol C<sub>60</sub>(OH)<sub>24</sub>

Toxicology Mechanisms and Methods
2009-01 | Journal article
DOI: 10.1080/01612840802203098
Part of ISSN: 1537-6516
Part of ISSN: 1537-6524
Contributors: Vukosava Djordjevic Milic; Karmen Stankov; Rade Injac; Aleksandar Djordjevic; Branislava Srdjenovic; Biljana Govedarica; Natasa Radic; Viktorija Dragojevic Simic; Borut Strukelj
Source: Self-asserted source
Rade Injac

Recent Advances in Protection against Doxorubicin-induced Toxicity

Technology in Cancer Research &amp; Treatment
2008-12 | Journal article
DOI: 10.1177/153303460800700611
Part of ISSN: 1533-0346
Part of ISSN: 1533-0338
Contributors: Rade Injac; Borut Strukelj
Source: Self-asserted source
Rade Injac

Potential hepatoprotective effects of fullerenol C60(OH)24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas

Biomaterials
2008-08 | Journal article
DOI: 10.1016/j.biomaterials.2008.04.048
Part of ISSN: 0142-9612
Contributors: Rade Injac; Martina Perse; Natasa Obermajer; Vukosava Djordjevic-Milic; Matevz Prijatelj; Aleksandar Djordjevic; Anton Cerar; Borut Strukelj
Source: Self-asserted source
Rade Injac

Cardioprotective Effects of Fullerenol C<sub>60</sub>(Oh)<sub>24</sub> on a Single Dose Doxorubicin-induced Cardiotoxicity in Rats with Malignant Neoplasm

Technology in Cancer Research &amp; Treatment
2008-02 | Journal article
DOI: 10.1177/153303460800700102
Part of ISSN: 1533-0346
Part of ISSN: 1533-0338
Contributors: Rade Injac; Martina Perse; Marija Boskovic; Vukosava Djordjevic-Milic; Aleksandar Djordjevic; Anastazija Hvala; Anton Cerar; Borut Strukelj
Source: Self-asserted source
Rade Injac

Influence of Fullerenol C&lt;sub&gt;60&lt;/sub&gt;(OH)&lt;sub&gt;24&lt;/sub&gt; on Doxorubicin Induced Cardiotoxicity in Rats

Materials Science Forum
2006-07 | Journal article
DOI: 10.4028/www.scientific.net/msf.518.525
Part of ISSN: 1662-9752
Contributors: V. Djordjević-Milić; A. Djordjević; S. Dobrić; Rade Injac; D. Vučković; Karmen Stankov; V. Dragojević-Simić; Lj. Suvajdžić
Source: Self-asserted source
Rade Injac
How many people are using ORCID?